About Amphivena Therapeutics

Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company that is developing a novel platform of dual-action biologics that relieve immune suppression and drive T-cell activation and polarization to restore anti-cancer immunity in patients

Science

Our science and platform target the suppressed immune system of cancer patients to restore anti-cancer immunity

The fundamental challenge in immuno-oncology is that a majority of patients do not respond to immunotherapies. Cancer patients exhibit tumor-induced immune suppression mediated by immune cell types such as myeloid derived suppressor cells (MDSC). T cell activating therapies can also trigger autoregulatory immune modulation, via MDSC recruitment.

Our proprietary platform is designed to potently and selectively deplete MDSC and to drive the activation and repolarization of T cells to relieve immune suppression and restore anti-cancer immunity in patients.

Platform

The AMPHIVENA ReSTORE™ platform provides dual-action biologics that relieve immune suppression and activate
T cell effector function in cancer patients

The platform can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing

Portfolio

Our lead candidate, AMV564, is currently in clinical studies in both solid tumor and hematologic cancers

We are advancing additional bivalent, multi-target candidates through preclinical development

Press Release
December 16, 2020

Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564

South San Francisco, CA – Dec 16, 2020 — Amphivena Therapeutics, a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, today announced the first patient has been dosed in the Phase 1 dose expansion study evaluating AMV564, an investigational, first-in-class agent that depletes myeloid derived suppressor cells (MDSC) and activates T cells, in adult patients with selected solid tumor indications….

Press Release
December 6, 2020

Novel AML patient selection assay for AMV564, Amphivena’s lead therapeutic in hematology, presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting

South San Francisco, CA – Dec 6, 2020 — Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, today presented data on a novel assay for selection of acute myeloid leukemia (AML) patients for treatment with AMV564, at the 62nd Annual American Society of Hematology Meeting and Exposition (ASH 2020), taking place virtually from December 5-8, 2020….

Press Release
November 9, 2020

Amphivena Presents Clinical Update And Translational Data Of AMV564 In Solid Tumor Patients At The 2020 Society For Immunotherapy Of Cancer (SITC) Annual Meeting

South San Francisco, CA – November 9, 2020 — Today Amphivena presented updated clinical and translational data for the lead clinical candidate, AMV564, from the AMPHIVENA ReSTORETM (Relieve Suppression of T cells in Oncology and Reinvigorate Effectors) platform of bivalent T-cell engagers, in two poster presentations at the SITC 2020 Annual Meeting…

Presentations & Publications